Front. Mol. Neurosci. Frontiers in Molecular Neuroscience Front. Mol. Neurosci. 1662-5099 Frontiers Media S.A. 10.3389/fnmol.2021.745275 Neuroscience Original Research Novel Functional Properties of Missense Mutations in the Glycine Receptor β Subunit in Startle Disease Piro Inken 1 † Eckes Anna-Lena 2 † Kasaragod Vikram Babu 3 Sommer Claudia 1 Harvey Robert J. 4 5 Schaefer Natascha 2 ‡ Villmann Carmen 2 * ‡ 1Department of Neurology, University Hospital Würzburg, Würzburg, Germany 2Institute for Clinical Neurobiology, University Hospital, Julius-Maximilians-University Würzburg, Würzburg, Germany 3Neurobiology Division, MRC Laboratory of Molecular Biology, Cambridge, United Kingdom 4School of Health and Behavioural Sciences, University of the Sunshine Coast, Maroochydore, QLD, Australia 5Sunshine Coast Health Institute, Birtinya, QLD, Australia

Edited by: Laura Astolfi, University of Padua, Italy

Reviewed by: Janosch P. Heller, Dublin City University, Ireland; Yuichiro Fujiwara, Kagawa University, Japan

 *Correspondence: Carmen Villmann, villmann_C@ukw.de

†These authors have contributed equally to this work and share first authorship

‡These authors have contributed equally to this work and share last authorship

This article was submitted to Molecular Signalling and Pathways, a section of the journal Frontiers in Molecular Neuroscience

 24 09 2021 2021 14 745275 21 07 2021 03 09 2021 Copyright © 2021 Piro, Eckes, Kasaragod, Sommer, Harvey, Schaefer and Villmann. 2021 Piro, Eckes, Kasaragod, Sommer, Harvey, Schaefer and Villmann

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Startle disease is a rare disorder associated with mutations in GLRA1 and GLRB, encoding glycine receptor (GlyR) α1 and β subunits, which enable fast synaptic inhibitory transmission in the spinal cord and brainstem. The GlyR β subunit is important for synaptic localization via interactions with gephyrin and contributes to agonist binding and ion channel conductance. Here, we have studied three GLRB missense mutations, Y252S, S321F, and A455P, identified in startle disease patients. For Y252S in M1 a disrupted stacking interaction with surrounding aromatic residues in M3 and M4 is suggested which is accompanied by an increased EC50 value. By contrast, S321F in M3 might stabilize stacking interactions with aromatic residues in M1 and M4. No significant differences in glycine potency or efficacy were observed for S321F. The A455P variant was not predicted to impact on subunit folding but surprisingly displayed increased maximal currents which were not accompanied by enhanced surface expression, suggesting that A455P is a gain-of-function mutation. All three GlyR β variants are trafficked effectively with the α1 subunit through intracellular compartments and inserted into the cellular membrane. In vivo, the GlyR β subunit is transported together with α1 and the scaffolding protein gephyrin to synaptic sites. The interaction of these proteins was studied using eGFP-gephyrin, forming cytosolic aggregates in non-neuronal cells. eGFP-gephyrin and β subunit co-expression resulted in the recruitment of both wild-type and mutant GlyR β subunits to gephyrin aggregates. However, a significantly lower number of GlyR β aggregates was observed for Y252S, while for mutants S321F and A455P, the area and the perimeter of GlyR β subunit aggregates was increased in comparison to wild-type β. Transfection of hippocampal neurons confirmed differences in GlyR-gephyrin clustering with Y252S and A455P, leading to a significant reduction in GlyR β-positive synapses. Although none of the mutations studied is directly located within the gephyrin-binding motif in the GlyR β M3-M4 loop, we suggest that structural changes within the GlyR β subunit result in differences in GlyR β-gephyrin interactions. Hence, we conclude that loss- or gain-of-function, or alterations in synaptic GlyR clustering may underlie disease pathology in startle disease patients carrying GLRB mutations.

 GLRB glycine receptor hyperekplexia startle disease gephyrin VI586 Deutsche Forschungsgemeinschaft 10.13039/501100001659 Medical Research Council 10.13039/501100000265 Action Medical Research 10.13039/501100000317 Medical Research Council 10.13039/501100000265 Introduction

Glycine receptors (GlyRs) enable fast synaptic inhibition in the adult brainstem and spinal cord of rodents and humans. In addition, GlyRs have been detected in the adult organism in the cortex, the retina, and inner ear (Lynch, 2004). GlyRs belong to the cys-loop ligand-gated ion channel superfamily that includes nicotinic acetylcholine receptors, GABAA/C receptors, and 5HT3 receptors. Cys-loop receptors are pentamers with a large N-terminal domain (NTD) composed of an N-terminal α-helix followed by 10 β-strands forming a twisted β-sheet arrangement, providing an immunoglobulin-like fold (Du et al., 2015; Huang et al., 2015; Yu et al., 2021). All receptor subunits have four transmembrane domains (TMD) followed by a short extracellular C-terminus. Transmembrane segments 1–4 (M1–M4) are connected by two small loops (M1–2 loop and M2–3 loop) and a large intracellular loop between M3 and M4 (Lynch, 2004). This loop is part of the intracellular domain (ICD) and of highest diversity among the subunits harboring specific domains for protein-protein interactions (Langlhofer and Villmann, 2016).

For GlyRs, four α subunits and one β subunit have been identified. GlyR α subunits can form functional homomeric channels located at extrasynaptic and presynaptic sites (Turecek and Trussell, 2001; Xiong et al., 2014). By contrast, β subunits only form functional ion channels when co-assembled with α subunits in heteromeric receptor complexes (Bormann et al., 1993). The subunit stoichiometry of heteromeric GlyRs has been described as 3α:2β pentameric assemblies (Durisic et al., 2012; Patrizio et al., 2017). During embryonic development, homomeric α2 subunit GlyRs represent the major GlyR isoform whereas after birth, subunit switches result in α1β and α3β as the major GlyR isoforms at postsynaptic sites (Liu and Wong-Riley, 2013; Morelli et al., 2017). Homomeric and heteromeric GlyRs also differ in their agonist and antagonist affinities (Grudzinska et al., 2005). Furthermore, Pribilla et al. (1992) demonstrated significant differences in the inhibition of the homomeric versus heteromeric GlyRs by the plant alkaloid picrotoxin. While homomeric α subunit GlyRs are blocked by picrotoxin, heteromeric αβ channels are almost unaffected (50–200-fold less effective) by the toxin (Pribilla et al., 1992).

During protein maturation, GlyR complexes fold and traffic through cellular compartments including the endoplasmic reticulum (ER), the ER-Golgi intermediate compartment (ERGIC) and the Golgi apparatus, with misfolded receptors retained in the ER (Schaefer et al., 2015, 2018). In neurons and transfected cells, α and β subunits are transported together with the scaffold protein gephyrin in a complex toward the neuronal membrane (Meyer et al., 1995; Meier et al., 2000; Patrizio et al., 2017). Residues 391–408 (numbering refers to precursor protein) localized in the M3-M4 loop of the GlyR β subunit enable gephyrin binding (Meyer et al., 1995; Maric et al., 2017).

Disruption of glycinergic neurotransmission is associated with neurological disorders including startle disease (hyperekplexia, OMIM 147100) and stiff person syndrome (SPS). The majority of cases of startle are caused by genetic variants in GLRA1 and GLRB (encoding the GlyR α1 and β subunits) or SLC6A5 encoding the glycine transporter 2 (GlyT2) (Rees et al., 2006; Chung et al., 2010, 2013; James et al., 2013; Bode and Lynch, 2014; Schaefer et al., 2015). By contrast, SPS patients suffer from impaired inhibitory neurotransmission following binding of GlyR-autoantibodies to the GlyR NTD (Carvajal-Gonzalez et al., 2014; Rauschenberger et al., 2020).

Genetic variants in GLRA1 and GLRB are inherited in either a dominant or recessive manner. Dominant mutations mainly affect ion channel function, e.g., ligand binding or channel opening, while most recessive mutations result in protein trafficking deficits (Villmann et al., 2009; Chung et al., 2010; Bode and Lynch, 2014; Schaefer et al., 2015). Mutations in the GLRB gene represent the third most common cause for startle disease. Homozygous null mutations including nonsense, small indels, frameshifts and splicing variants have been described. Moreover, missense mutations P169L, M177R, L285R, W310C, and Y470C located in the extracellular domain (ECD), the M2, M3, or M4 domains resulted in reduced expression levels and impaired GlyR function including reduced glycine sensitivity and maximal glycine-gated currents (Chung et al., 2013; James et al., 2013).

Here, we investigated three GlyR β variants Y252S, S321F, and A455P from patients with startle disease (Lee et al., 2013; Aboheimed et al., 2019). Mutations have been analyzed using protein biochemical and immunocytochemical analyses, electrophysiological recordings and homology modeling. All three β subunit variants did not show any major trafficking defects. Co-expression with gephyrin resulted in recruitment of GlyR β variants (βX) Y252S, S321F, and A455P to gephyrin clusters in transfected HEK-293 cells. At the structural level, Y252S disrupts stacking interactions with surrounding residues of M3 and M4, while S321F most probably stabilizes stacking interactions with other aromatic residues in M3. Functional heteromeric α1βX GlyRs displayed reduced agonist potencies or significantly enhanced maximal chloride ion influx upon activation with glycine thus demonstrating a contribution of the identified β subunit mutations to the startle disease phenotype in affected patients.

 Materials and Methods Homology Modeling and Sequence Alignment

For the modeling of the heteromeric αβ glycine receptor, the recent cryo-EM structures of the homomeric α1 subunit GlyR (PBD:6VM0) (Yu et al., 2021) was taken as the template for the pentameric arrangement. The same structure was used for homology modeling of the GlyR β subunit using SWISS-MODEL (Arnold et al., 2006). The stoichiometry of the heteromeric 3α:2β is based on the stoichiometry proposed by Patrizio et al. (2017) to exclude the β-β interface in the heteropentameric arrangement. Mutations in the β subunit were carried in Coot (Emsley and Cowtan, 2004) by taking into consideration the most probable rotamer conformation by considering clashes with the surrounding residues and retaining the geometry of the mutated residue. Structural figures were prepared using ChimeraX (Goddard et al., 2018). Alignments were performed using T-COFFEE web server (Version 11.00, (Notredame et al., 2000; Di Tommaso et al., 2011).

 Molecular Cloning

Full-length cDNAs encoding the human wild-type (WT) or mutated GlyR β variants (βx) (with x = Y252S, S321F, and A455P) were cloned into the eukaryotic expression vector pRK5 (gift from †P. Seeburg, Heidelberg) and mutagenesis was performed as previously described (James et al., 2013). GlyR β variants were further subcloned into pRK5 harboring a myc-epitope at the N-terminus 5′ of residues 1KEKS4 representing the first amino acids of the mature GlyR β sequence. eGFP-gephyrin constructs were previously described (Harvey et al., 2004). All expression constructs were fully sequenced to verify successful mutagenesis.

 Cell Lines

HEK-293 cells (Human Embryonic Kidney cells; CRL-1573; ATCC – Global Biosource Center, Manassas, VA, United States) were grown in minimum essential medium (Life Technologies) and COS-7 cells (African Green Monkey Kidney cells; CRL-1651; ATCC – Global Biosource Center, Manassas, VA, United States) were grown in Dulbecco’s modified eagle medium (Life Technologies), both supplemented with 10% fetal bovine serum, L-glutamine (200 mM) and 50 U/ml penicillin and 100 μg/mL streptomycin at 37°C and 5% CO2.

 Preparation of Hippocampal Neurons

Neurons were prepared from wild-type CD-1 mice at the embryonic stage 16 (E16). Experiments were approved by the local veterinary authority (Veterinäramt der Stadt Würzburg, Germany) and the Ethics Committee of Animal Experiments, i.e., Regierung von Unterfranken, Würzburg, Germany (license no.: FBVVL 568/200-324/13). Briefly, murine embryos were taken out of the euthanized mother mouse and dissected under a binocular microscope. Hippocampi were dissected out of the embryos and collected in neurobasal medium (21103-049 Life Technologies, Waltham, MA, United States) on ice. Following collection, the tissue was trypsinized using 5 ml of trypsin/EDTA (1 mg/ml) and 50 μl of DNase I (final concentration, 0.1 mg/ml), incubating the suspension at 37°C for 30 min. Trypsinization was stopped with 500 μl of fetal calf serum (final concentration, 10%). After a three-step trituration protocol, the cells were centrifuged at 800 rpm for 15 min. Trituration steps were repeated. Neurons were seeded in 3 cm dishes containing four poly-L-lysine coated coverslips in a density of 150,000 cells per dish. Neurons were grown in neurobasal medium supplemented with 1% 200 mM L-glutamine (25030-024 Life Technologies, Waltham, MA, United States) and 1% B27 (17504-044 Life Technologies, Waltham, MA, United States) with an exchange of 50% medium after 6 days in culture.

 Transfection of Cell Lines and Primary Neurons Transfection of HEK-293 Cells

HEK-293 cells were transiently transfected using a modified calcium-phosphate precipitation method. Transfection was performed at a confluency of 50–75%, 24 h after seeding of 200,000 cells on glass cover slips in 35 mm culture dishes or 1.5 × 106 cells per 10 cm dish. For 35 mm and 10 cm culture dishes GlyR α1, GlyR β or GlyR β variants and eGFP-gephyrin were transfected in a ratio of cDNAs 1:10:5, e.g., 0.2 μg α1, 2 μg β, and 1 μg of eGFP-gephyrin for 35 mm dishes. To label cellular compartments, low copy number vectors were used to exclude effects from overexpression [1 μg; dsRed MEM = fusion of sequence from neuromodulin (GAP-43) and dsRed to label the plasma membrane or dsRed ER = fusion construct of dsRed and calreticulin sequence to label the ER]. The DNA was supplied with 2.5 M CaCl2, 0.1x TE buffer and 2x HBS buffer (50 mM HEPES, 12 mM glucose, 10 mM KCl, 280 mM NaCl, 1.5 mM Na2HPO4) mixed and incubated for 20 min at room temperature. The medium was exchanged after 4–6 h and cells were used for experiments 24–48 h after transfection.

 Transfection of COS-7 Cells

COS-7 cells were transfected using a DEAE-Dextran transfection protocol. 150,000 cells were seeded on glass cover slips in 35 mm dishes 24 h before transfection. 0.2–2 μg plasmid DNA (same amounts were used as for transfection of HEK-293 cells) in PBS and 10 mg/ml DEAE-Dextran were mixed and added to the cells. After an incubation of 30 min at 37°C, cells were washed and 2 ml culture medium with 10 mM chloroquine were added to the cells. The medium was exchanged again after 2 h and cells were used for immunocytochemical stainings 24–48 h after transfection.

 Transfection of Hippocampal Neurons

Hippocampal neurons were transfected 3 days after plating using a modified calcium-phosphate precipitation method. 2 μg of DNA (1 μg/μl), 2.5 μl CaCl2 (2.5 M), 70 μl Ampuwa water and 25 μl 2xBBS (50 mM BES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 7.05) were mixed and incubated for 30 min in the dark. Meanwhile, the neuronal medium was aspirated from the hippocampal culture and stored until the end of transfection. Neurons were transfected with the transfection mixture (α1:β in a ratio of 1:5) supplemented by additional 450 μl neurobasal medium for 30 min incubated in the cell culture incubator. The transfection mixture was aspirated, the cells washed twice with Hank’s Balanced Salt Solution (HBSS) medium and flooded with the original neuronal medium. Neurons were used for immunocytochemical staining at DIVs 17–21.

 Immunocytochemical Stainings

Transfected HEK-293, COS-7 cells or hippocampal neurons were fixed using 4% paraformaldehyde with 4% sucrose in phosphate-buffered saline (PBS) for 20 min at room temperature. After washing for three times with PBS, cells were blocked and permeabilized with 5% goat serum with 0.2% Triton-X-100 in PBS for 30 min. Primary antibodies against myc-tagged GlyR β (Synaptic Systems, Göttingen, Germany, 303008, 1:250), Golgi/GM130 (BD Transduction Laboratories, Heidelberg, Germany, 610822, RRID:AB_398141, 1:250), ERGIC-53 (Enzo, ALX-804-602-C100, RRID:AB_2051363, 1:250), gephyrin (Synaptic Systems, Göttingen, Germany, 147111, RRID:AB_887719, 1:100) and synapsin (Synaptic Systems, Göttingen, Germany, 106006, RRID:AB_2622240, 1:500) were diluted in PBS containing 5% normal goat serum and incubated for 1 h, followed by incubation of secondary antibodies goat-α-rabbit-Alexa-488 (Dianova, Hamburg, Germany, 111-546-003, RRID:AB_2338053), goat-α-mouse-Alexa-488 (Dianova Hamburg, Germany, 115-546-003, RRID:AB_2338859), goat-α-mouse-Cy3 (Dianova, Hamburg, Germany, 115-165-003, RRID:AB_2338680), goat-α-rabbit-Cy3 (Dianova, Hamburg, Germany, 111-165-003, RRID:AB_2338000), donkey-α-chicken-Alexa 647 (Dianova, Hamburg, Germany, 703-605-155, RRID:AB_2340379) and goat- α-rabbit-Cy5 (Dianova, Hamburg, Germany, 111-175-006) diluted 1:500 in PBS containing 5% goat serum for 1 h in the dark. After another washing step with PBS, cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) in PBS for 5 min. Cells were washed again with PBS and ddH2O and mounted on a microscope slide in Mowiol.

 Image Analysis

Images of immunocytochemical stainings were captured using an Olympus Fluoview ix1000 microscope with an UPLSAPO 60x oil objective and diode lasers of 405 nm, 495 nm and 550 nm. All images were captured with 1024 × 1024 pixels. For image analysis and processing (eGFP-gephyrin cluster analysis, synapse colocalization, and Western blot quantification) the Fiji/ImageJ Software was used (Schindelin et al., 2012).

 Biotinylation Assay and Immunostaining

Transiently transfected HEK-293 cells co-expressing wild-type GlyR α1β, α1βx variants or α1β together with eGFP-gephyrin were used. 48 h after transfection, medium was removed, and cells were washed three times with ice-cold PBS (GE Healthcare, Freiburg, Germany). The surface proteins were labeled by incubating the cells (10 cm dish) for 30 min with 1 mg/mL EZ-Link Sulfo-NHS-LC-biotin [sulfosuccinimidyl-6-(biotinamido)hexanoate, Pierce Biotechnologies, Rockford, IL, United States], followed by incubation with quenching buffer (192 mM glycine, 25 mM Tris in PBS, pH 8.0) for 10 min. Cells were detached by using ice-cold PBS buffer followed by centrifugation for 10 min at 1,000 × g. Cell lysis was performed with TBS (Tris–buffered saline) with 1% Triton-X100 and protease inhibitor mixture tablet (Roche Diagnostics, Mannheim, Germany) and centrifuged for 1 min at 13,000 × g. The supernatant (whole protein fraction) was incubated with 50 μl of streptavidin-agarose beads (Pierce Biotechnologies, Rockford, IL, United States) for 2 h at 4°C while rotating. After removing the supernatant, beads were washed three times in TBS buffer. Biotinylated proteins were eluted by boiling with 50 μl of 2x SDS buffer for 5 min at 95°C. 40 μg of surface proteins were analyzed by Western blot.

 SDS-PAGE and Western Blot

Proteins samples were separated by SDS-PAGE using 11% (w/v) gels followed by transfer of separated proteins onto a nitrocellulose membrane (GE Healthcare, Little Chalfont, United Kingdom). After blocking for 1 h with 5% BSA in TBS-T (TBS with 1% v/v Tween 20), membranes were incubated with primary antibodies over night at 4°C (anti-GlyRβ, Synaptic Systems, Göttingen, Germany, 146211, 1:200) or (anti-gephyrin, Synaptic Systems, Göttingen, Germany, 147111, 1:100). Pan-cadherin (Cell Signaling Technology, Danvers, MA, United States, 4068, 1:1,000) or GAPDH (Merck, Darmstadt, Germany, CB 1001, 1:1,000) served as a loading control. Proteins were visualized with the help of horseradish peroxidase (111-036-003 and 115-035-146, Dianova, Hamburg, Germany) and detected through chemiluminescence using clarityTM Western ECL substrate (Clarity Western Peroxide Reagent, Bio-Rad 170-5061, Hercules, CA, United States).

 Electrophysiological Recordings

Electrophysiological characterization was performed on transfected HEK-293 cells using the patch-clamp method for whole cell recordings. Experiments were performed at room temperature. Recording pipettes were pulled from borosilicate capillaries, had an open resistance of 3.5–5.5 MΩ and were filled with internal Buffer [120 mM CsCl, 20 mM N(Et)4Cl, 1 mM CaCl2, 2 mM MgCl2, 11 mM EGTA, 10 mM HEPES; pH 7.2, adjusted with CsOH]. For determination of maximal current amplitudes (Imax) and EC50 values, glycine was applicated in concentrations of 10 μM, 30 μM, 60 μM, 100 μM, 300 μM, 600 μM, 1 mM in external buffer (137 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES; pH 7.35, adjusted with NaOH). Glycine concentrations were introduced by an OctaFlow II system (ALA Scientific Instruments, Farmingdale, NY, United States) for 50 ms at 15 PSI. After increasing glycine concentrations, 100 μM picrotoxinin (Sigma-Aldrich, Darmstadt, Germany) + 100 μM glycine in external buffer was applied in the same manner. Current responses were amplified with an EPC-9 amplifier (HEKA Elektronik GmbH, Lambrecht/Pfalz, Germany) and measured at a holding potential of −60 mV using PatchMaster Next software (HEKA Elektronik GmbH, Lambrecht/Pfalz, Germany). Maximal current amplitudes blocked by picrotoxinin of at least 50% of the initial current following glycine application alone was deemed to represent homomeric GlyRs, and were thus excluded from analysis.

 Statistical Analysis

Data were analyzed using Graph Pad Prism or Origin 9 Software and are represented as mean ± SEM (standard error of the mean).

Electrophysiological recordings of transfected cells were performed from at least three different experiments. The numbers of recorded cells are displayed in the figure legends. All other experiments were performed at least three times if not stated elsewhere. Normality of the data was reviewed by Shapiro–Wilk normality test (α = 0.05). Statistical significance was calculated using an unpaired two-tailed Mann–Whitney test or an unpaired t-test, depending on the data sets to be analyzed. The χ2-test was used for statistical analysis of GlyR subunit compositions during electrophysiological recordings. All p-values are given in the section “Results.” The 0-hypothesis was rejected at a level of p < 0.05.

 Results Novel Glycine Receptor β Mutations Interfere With Stacking Interactions Within the α-Helical Transmembrane Domains and Are Predicted to Affect Protein Stability

To understand the possible impact of the GlyR β subunit Y252S, S321F, and A455P mutations on the protein structure and functions, we generated a homology model of the 3α:2β heteropentamer (Figure 1). The reported mutations are located in the transmembrane domains M1 to M4 of the GlyR β subunit (Figures 1A–E). In the series of mutations, Y252 (Y252 corresponding to Y274 in the precursor protein including the signal peptide) is located in M1 (Figures 1A,D,E). In the wild-type subunit, this residue is a part of a hydrophobic quadrant with a stacking interaction with W332 from the M3 and van der Waals interactions with Y492 and W493 from M4. In addition, Y252 comes in close proximity to P191, a residue located in the cys-loop of the subunit. Mutation of aromatic tyrosine with hydrophilic serine (Figure 1E), on the one hand might impact the folding of the subunit considering the environment of the residue and also the shorter serine side chain loses the contact to P191 from the cys-loop, which in turn might deregulate the gating properties of the receptor. By contrast, S321 (S321 corresponds to S343 in the precursor) is located in M3 and surrounded by aromatic residues. Mutation of this serine into a bulkier phenylalanine, might in turn favor the hydrophobic environment and provide additional stability into the interactions of M3 with M1 and M4 helices (Figures 1A,D,E). Another mutation resides in a residue located in M4 helix, A455 (A455 corresponding to A477 in the precursor) (Figures 1A,D,E). A mutation in this surface-exposed alanine into proline (Figure 1E) can be speculated not to cause any direct impact on the folding of the subunit, yet the proline might produce a kink in the helix which will in turn compromise the interaction of the subsequent residues in the M4 with its surrounding residues in M1 and M3 helices.

Molecular modeling of novel GlyR β subunit mutants. (A) Alignment of GlyR subunits α1, α2, α3, β subunits from human and the β subunit variants concentrating on transmembrane segments. Numbers of amino acid residues in mutant variants refer to non-mature protein, (SP) signal peptide. (B–D) Cartoon representation of the 3α:2β glycine receptor heteropentamer homology model viewed from extracellular domain (B), from the intracellular side (C) and the membrane plane (D). GlyR α-subunits are colored orange and yellow and β-subunits are colored in green. (E) Close-up views of the interaction of residues in WT (left panels) and the mutant (right panels) model. All critical residues are shown as ball and stick, whereas the backbone is shown in cartoon representation, numbering refers to mature protein.

 Trafficking of Glycine Receptor α1β Heteromers to the Cell Surface Is Unaltered for Y252S, S321F, and A455P

The GlyR α1 subunit is transported together with the β subunit to the cellular surface. To investigate an impairment in trafficking, a compartmental analysis was performed in transfected HEK-293 or COS-7 cells. The later were used if the ER-Golgi intermediate compartment (ERGIC) or the cis-Golgi (GM130) were stained as COS-7 cells provide a larger cytoplasm. In addition, the ER and the plasma membrane localization were studied. When co-expressed as heteromers, α1βY252S, α1βS321F, and α1βA455P exhibited intensive staining in the ER followed by ERGIC and cis-Golgi labeling. For all three mutants, membrane staining co-localized with the membrane marker GAP-43 was observed (Figure 2A). Quantitative Western blot analysis from total cell lysates of transfected HEK-293 cells also revealed reduced, but non-significant differences in the whole-cell expression levels between wild-type α1β and the β mutants α1βY252S 58 ± 2%, α1βS321F 72 ± 7% and α1βA455P 98 ± 18% (Figure 2B and Table 1). No significant reduction of the whole cell protein has also been observed for other startle disease mutations affecting either the α1 or the β subunit (Chung et al., 2013; Atak et al., 2015).

Subcellular expression and trafficking of GlyR β mutants. (A) Immunocytochemical staining of HEK-293 (upper two lanes) or COS-7 cells (lower lanes) transfected with GlyR α1 and β WT or β subunit variants (1:10 = α1 WT:β WT or βx variant with x = either Y252S, S321F, or A455P). GlyR β or βx variants were stained with an anti-myc antibody (cyan), cellular compartment marker (GAP-43: cell membrane, calreticulin (Cal): endoplasmic reticulum, ERGIC: ER-Golgi intermediate compartment, GM130: Golgi) are always shown in magenta. Enlargements (marked by white box) are provided on the right next to each image, arrow heads point to co-localization or accumulation of both labeled proteins. Scale bars refer to 10 μm. (B) Representative Western blot of whole cell protein lysates from HEK-293 cells transfected with α1 WT and β WT or βx variants in a ratio of 1:2. GlyR β is detected at 58 kDa. Pan-cadherin (Pan-Cad) served as loading control (130 kDa). (C) Quantitative analysis of GlyR β and βx variants from whole cell lysates (n = 3, three independent experiments) of co-expressed GlyR α1 together with the GlyR β subunit (red bar) or GlyR βx variants (black bars).

Expression of GlyR β variants in the presence and absence of gephyrin in transfected cells.

GlyR variant Whole cell GlyR β (%) p-values n GlyR variant + eGFP gephyrin whole cell geph (%) p-values Surface fraction geph (%) p-values n
GlyR α1β 100 ± 17 3 GlyR α1β 100 ± 28 100 ± 23 4
GlyR α1βY252S 58 ± 2 p = 0.07 3 GlyR α1βY252S 136 ± 37 p = 0.5 191 ± 53 p = 0.2 4
GlyR α1βS321F 72 ± 7 p = 0.2 3 GlyR α1βS321F 191 ± 51 p = 0.2 190 ± 42 p = 0.1 4
GlyR α1βA455P 98 ± 18 p = 0.9 3 GlyR α1βA455P 209 ± 39 p = 0.6 168 ± 13 *p = 0.043 4

Significance values: *p < 0.05, n = number of experiments.

 Expression of Heteromeric α1β Glycine Receptors Reveal Altered Ion Channel Function for Y252S, S321F, and A455P

A reduction of whole cell β subunit does not necessarily equate to reduced glycine-gated chloride ion influx on overexpression of GlyRs in HEK-293 cells. Therefore, we tested the functionality of the heteromeric GlyR α1βx channels. To prove heteromeric receptor expression, picrotoxinin, an GlyR ion channel blocker, was applied together with the agonist (100 μM glycine + 100 μM picrotoxinin) and compared to glycine (100 μM) application alone. If GlyR α1 homomers were measured, the observed block of the glycine-gated response led to a reduction in current amplitude of 29.22% of the original value. By contrast, the observed picrotoxinin block of α1βx channels was in a range of 0–19% meaning residual currents of 81–99% (Figure 3A and Table 2). Thus, cells expressing “heteromeric” GlyRs with a picrotoxinin block larger than 50% were excluded from the analysis, since it was likely that these expressed a significant portion of homomeric α1 subunit GlyRs. At saturating glycine concentrations (600 μM), the maximal current amplitudes for α1βY252S and α1βS321F were indistinguishable from α1β while α1βA455P exhibited a gain-of-function, as current amplitudes more than doubled in comparison to the α1β WT receptor (9.5 ± 1.2 nA for α1βA455P compared to 4.1 ± 0.4 nA for α1β; p = 0.0012; Figure 3B and Table 2). Estimation of the dose-response relationship for the agonist glycine determined a significant increase in the glycine EC50 value for the heteromeric receptors α1βY252S (146 ± 17 μM, p = 0.0200; Figures 3C–I and Table 2) and thus a decrease in glycine potency. Mutants α1βS321F and α1βA455P did not result in a change of glycine potency (Figures 3E,F). Normalization of the dose-response curve to the maximal currents obtained from α1β suggested a gain-of-function for α1βA455P (Figures 3G–I).

Glycine receptor β subunit mutants alter functional properties of the chloride channel. Electrophysiological measurements of transfected HEK-293 cells. GlyR α1 alone (green bar), co-transfection of α1 and β WT (red bar) or β variants (Y252S, S321F, and A455P; black bars). (A) Block of the glycine-gated response using 100 μM glycine and 100 μM of picrotoxinin. Bars show residual currents after picrotoxinin block normalized to currents evoked by 100 μM glycine application. Dotted line shows cut-off for determination of heteromeric receptor configuration. Only cells above the cut-off were used for analysis. (B,C) Imax and EC50 mean values are depicted. (D–F) Dose-response curves for α1β (red line) or α1βx variants [Y252S (D), S321F (E), and A455P (F); black lines] using increasing glycine concentrations (10, 30, 60, 100, 300, 600, and 1,000 μM). Values were normalized to the Imax mean value of the according α1β variant following application of 1,000 μM glycine. (G–I) Dose-response curves of α1β (red line) or α1βx variants [(G) Y252S, (H) S321F, and (I) A455P black lines] normalized to WT α1β Imax mean value following application of 1,000 μM glycine. Representative traces at 1,000 μM glycine application of α1β (red traces) and α1βx variants are depicted in the upper left corner of each diagram. Significance values are *p < 0.05, **p < 0.01, and ***p < 0.001.

Electrophysiological properties of GlyR α1β and α1βx variants.

GlyR variant Glycine EC50 (μM) Imax (nA) I 100 μM picrotoxinin + glycine/I 100 μM glycine (%) p-values EC50 p-values Imax n
GlyR α1β 99 ± 8 4.1 ± 0.4 90 ± 11 9
GlyR α1βY252S 146 ± 17 4.7 ± 0.6 99 ± 19 *p = 0.02 p = 0.47 9
GlyR α1βS321F 104 ± 11 5.1 ± 0.7 111 ± 15 p = 0.97 p = 0.29 12
GlyR α1βA455P 91 ± 8 9.5 ± 1.2 86 ± 10 p = 0.49 **p = 0.0012 12

Significance values: *p < 0.05; **p < 0.01, n = number of experiments.

 Glycine Receptor β Variants Y252S, S321F, and A455P Are Recruited to Gephyrin Aggregates in Transfected Mammalian Cells

The GlyR β subunit interacts via a short sequence (R416–S433) in the M3-M4 intracellular loop with the scaffold protein gephyrin. This interaction is a prerequisite for synaptic localization of the GlyR complex (Meier and Grantyn, 2004). Altered synaptic localization could therefore also underlie a startle disease phenotype at the molecular level. We co-expressed the α1βx combinations together with eGFP-tagged gephyrin (eGFP-gephyrin) in transfected HEK-293 cells. When transfected alone, the construct eGFP-gephyrin forms large highly intense intracellular aggregates (Figure 4A, left panels) (Harvey et al., 2004). Upon co-transfection with the GlyR α1β, these intracellular aggregates are still evident, but were either dispersed or multiple aggregates were formed, arguing for recruitment of the GlyR β subunit to gephyrin accumulations. Interestingly, all β subunit variants Y252S, S321F, and A455P were also recruited to the gephyrin aggregates seen by intense co-localization of eGFP-gephyrin and β subunits (Figure 4A). Gephyrin accumulations were analyzed for number, area and perimeter (Figures 4B–D). The GlyR β WT subunit as well as the βx subunit variants led to significantly enhanced gephyrin aggregate numbers accompanied with decreased aggregate areas in line with recruitment of the GlyR β mutants Y252S, S321F, and A455P together with gephyrin (Figure 4B and Table 3). Similarly, the gephyrin aggregate perimeter was reduced in the presence of α1β and α1βx variants (Figure 4D). A comparison of the gephyrin aggregates between α1β and the β variants revealed a significant increase in the aggregate area and aggregate perimeter for α1βS321F (area: 1911 ± 165 μm2, p = 0.00037 compared to α1β WT with 1480 ± 195 μm2; perimeter: 5503 ± 290 μm, p = 0.00059 compared to α1β WT 4497 ± 348 μm, Table 3). In addition to the gephyrin accumulations, the GlyR β subunit was also targeted to intracellular eGFP-gephyrin aggregates in co-expression experiments with the α1 subunit, in contrast to previous immunostainings in the absence of eGFP-gephyrin (Figures 2, 4A). The analysis of the GlyR β subunit aggregation revealed a significantly decreased number for the variant βY252S (9 ± 1 in comparison to α1β WT 14 ± 1; p = 0.0062, Table 3). The β subunit aggregate area was enlarged for mutants βS321F and βA455P (2059 ± 171 μm2 with p = 0.03 for βS321F or 2202 ± 180 μm2 with p = 0.0017 for βA455P; compared to α1β WT with 1605 ± 151 μm2; Table 3) while the perimeter was only significantly increased for βA455P (6234 ± 309 μm, p = 0.011 compared to α1β WT 5310 ± 303 μm; Figures 4E–G and Table 3). The observed alterations in number, area and perimeter of the GlyR βx subunit accumulations in eGFP-gephyrin aggregates may have an impact on GlyR biogenesis and finally receptor functionality. The images represent large intracellular GlyR β accumulations with no distinct labeling of the cellular membrane. Membrane expression of the GlyR β variants was revealed in the presence of eGFP-gephyrin and a co-transfected membrane marker (GAP-43). While the GlyR β WT was nicely expressed at the cellular membrane (Figure 5A, upper lane), GlyR βY252S exhibited both cell surface expression and ER retention (co-localized with calreticulin) and formed large aggregates together with gephyrin. Mutants βS321F and βA455P were also expressed at the membrane but mainly detectable intracellularly (Figure 5A, lower two lanes). We failed to detect the β variants by Western blot. Instead, we used the tight association between GlyR β and gephyrin to measure gephyrin expression in the surface fraction probably still attached to β following a biotinylation assay. Expression of gephyrin alone, did not result in any detectable gephyrin in the membrane fraction (Figure 5D). However, in the presence of the α1βx, gephyrin was detectable in both the whole cell and membrane fractions (Figures 5B–D). When co-expressed with α1βY252S and α1βS321F, gephyrin levels in the cell-surface fraction were indistinguishable from the WT α1β level. However, a significant increase of gephyrin was observed when co-expressed with α1βA455P (Figures 5C,D). Thus, although the co-expression with gephyrin led to larger intracellular accumulations of the βx variants, surface expression suggests the formation of functional GlyRs at the cellular membrane.

GlyR β variants for cytoplasmic aggregates in the presence of gephyrin. (A) Immunocytochemical stainings of HEK-293 cells transfected with eGFP-gephyrin alone or GlyR α1, eGFP-gephyrin and β WT or β variants (Y252S, S321F and A455P; ratio 1:5:10). Myc-tagged GlyR β WT or missense variants were stained with a specific anti-myc antibody (cyan, lower lane), eGFP-gephyrin is shown in yellow (middle lane), merge images are depicted in the upper lane. Nucleus is marked in blue (DAPI). Scale bar refers to 10 μm in all images. (B–G) Bar graphs of gephyrin aggregate analysis of HEK-293 cells expressing eGFP-gephyrin (blue bars), eGFP-gephyrin and α1β WT (red bars) or eGFP-gephyrin and α1β variants (black bars): (B) number of gephyrin aggregates, (C) area of gephyrin aggregates, (D) perimeter of gephyrin aggregates, (E) number of β (c-myc) aggregates, (F) area of β (c-myc) aggregates, (G) perimeter of β (c-myc) aggregates, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Quantification of GlyR β and gephyrin accumulations in transfected cells.

GlyR variant Number of geph aggregates/cell p-values compared to only gephyrin p-values compared to GlyR α1β n Number of myc aggregates/cell p-values compared to GlyR α1β n
only gephyrin 2 ± 0.2
GlyR α1β 8 ± 2 ****p < 0.0001 16 14 ± 1 16
GlyR α1βY252S 6 ± 1 ****p < 0.0001 p = 0.5 15 9 ± 1 **p = 0.0062 15
GlyR α1βS321F 8 ± 1 ****p < 0.0001 p = 0.9 17 11 ± 2 p = 0.07 17
GlyR α1βA455P 10 ± 1 ****p < 0.0001 p = 0.1 16 14 ± 2 p = 0.7 16
GlyR variant Mean area per geph aggregate (μm2) p-values compared to only gephyrin p-values compared to GlyR α1β n Mean area per myc aggregate (μm2) p-values compared to GlyR α1β n
only gephyrin 3837 ± 523
GlyR α1β 1480 ± 195 ****p < 0.0001 16 1605 ± 151 16
GlyR α1βY252S 1925 ± 253 ****p < 0.0001 p = 0.057 15 1991 ± 215 p = 0.1 15
GlyR α1βS321F 1911 ± 165 ****p < 0.0001 ***p = 0.00037 17 2059 ± 171 *p = 0.03 17
GlyR α1βA455P 1611 ± 157 ****p < 0.0001 p = 0.054 16 2202 ± 180 **p = 0.0017 16
GlyR variant Mean perimeter per geph aggregate (μm) p-values compared to only gephyrin p-values compared to GlyR α1β n Mean perimeter per myc aggregates (μm) p-values compared to GlyR α1β n
only gephyrin 6703 ± 511
GlyR α1β 4497 ± 348 ****p < 0.0001 16 5310 ± 303 16
GlyR α1βY252S 5245 ± 405 **p = 0.0057 p = 0.058 15 5674 ± 372 p = 0.3 15
GlyR α1βS321F 5503 ± 290 *p = 0.016 ***p = 0.00059 17 5814 ± 292 p = 0.8 17
GlyR α1βA455P 4507 ± 244 ****p < 0.0001 p = 0.2 16 6234 ± 309 *p = 0.011 16

Significance values: *p < 0.05; **p < 0.01, ***p < 0.001, ****p < 0.0001, n = number of counted cells.

Membrane expression of GlyR β variants is altered in the presence of gephyrin. (A) HEK-293 transfected with GlyR α1, eGFP-gephyrin and β WT or βx variants (Y252S, S321F or A455P). Cellular compartment markers (GAP-43: cell membrane, calreticulin (Cal): endoplasmic reticulum) are always co-transfected (magenta). GlyR β WT or variants are stained with an anti-myc antibody (cyan), eGFP-gephyrin is shown in yellow. White boxes mark the areas shown in the enlarged images. Arrow heads point to co-localization or accumulation of eGFP-gephyrin and β WT or β variants. Scale bars refer to 10 μm. (B,C) Quantitative analysis of eGFP-gephyrin in whole cell fraction (B) and surface (C) fractions (n = 4, four independent experiments) of co-expressed GlyR α1 together with β WT (red bar) or GlyR β variants (black bars) and eGFP-gephyrin. (D) Representative Western blots of whole cell and surface fractions from transfected HEK-293 cells. eGFP-gephyrin (geph) is detected at the appropriate molecular weight of 93 kDa, Pan-cadherin (Pan-Cad) served as loading control for surface fraction (130 kDa) and GAPDH served as loading control for whole cell fraction (30 kDa). Level of significance *p < 0.05.

 Interaction With Gephyrin Does Not Further Impact Glycine Receptor Functionality

Whole-cell electrophysiology measurements revealed a larger fraction of homomeric α1 GlyRs in cells transfected with α1β and gephyrin compared to cells transfected with α1β alone (Figures 6A,B). Around 40.9% of all cells recorded following transfection of α1β WT or α1βx variants together with eGFP-gephyrin expressed homomeric α1 GlyRs. This is perhaps to be expected given that homomeric α1 subunit GlyRs can escape intracellular “trapping” by intracellular eGFP-gephyrin aggregates. However, clear differences were observed between the WT β subunit and the βx variants in the presence of α1 and gephyrin. While the homomeric α1 receptor portion is similar between α1β WT and α1β WT plus gephyrin, for all three βx variants a larger portion of α1 homomers was detected in the presence of gephyrin (co-expressed α1βY252S p = 0.274; α1βS321F p = 0.0565; α1βA455P p = 0.0228; Figure 6B). Hence, βx variants appear to preferentially target to intracellular gephyrin aggregates, hindering the formation of heteromeric α1β cell-surface GlyRs. The maximal chloride currents at saturating glycine concentration were again significantly increased for the α1βA455P variant confirming A455P as a gain-of-function mutation (Imax 6.6 ± 1.1 nA; compared to α1β with 2.9 ± 1.0 nA, p = 0.0270; Figure 6C and Table 4). For α1βY252S, the enhanced EC50 value was even more pronounced in the presence of gephyrin (EC50 241 ± 27 μM; compared to α1β with 120 ± 12 μM, p = 0.0009; Figures 6D,E and Table 4). Hence, the observed functional alterations for the GlyR β variants were also detectable in a heteromeric complex with GlyR α1 and gephyrin.

GlyR functional properties do not change in the presence of gephyrin. (A) Verification of heteromeric receptor configuration using picrotoxinin block. GlyR α1β WT and α1βx variants were co-expressed with eGFP-gephyrin in HEK-293 cells. The remaining current (%) upon co-application of 100 μM glycine and 100 μM picrotoxinin compared to 100 μM glycine alone is shown. Dotted blue line at 50% picrotoxinin block divides between homomeric (below blue line) and heteromeric (above blue line) receptor configuration. (B) Stack plot of the ratio between homomeric (green) and heteromeric (black) receptor configurations of α1β WT and α1βx variants in the absence and presence of eGFP-gephyrin. Significance value *p < 0.05. (C) Glycine-activated currents at saturating glycine concentration (1 mM). Note, the GlyR βA455P variant again exhibited significantly increased Imax values. (D) EC50 values for α1β WT and α1βx variants in the presence of eGFP-gephyrin were determined following application of a concentration series of glycine (10, 30, 60, 100, 300, 600, and 1,000 μM). (E) Dose response curves of α1βY252S shows a rightward shift to higher glycine concentration compared to α1β WT in the presence of eGFP-gephyrin. *p < 0.05, ***p < 0.001.

Physiological measurements of α1β and α1βx variants in the presence of gephyrin in transfected cells.

GlyR variant Glycine EC50 (μM) n p-values EC50 Imax (nA) n p-values Imax Ipicrotoxinin + glycine/ Iglycine (%) Homomers without gephyrin co-expression (%) Homomers with gephyrin co-expression (%) p-values n
GlyR α1β 120 ± 12 9 2.9 ± 1.0 9 72 ± 7 60 52 p = 0.6 3
GlyR α1βY252S 241 ± 27 9 ***p = 0 0009 3.7 ± 0.9 9 p = 0.30 84 ± 9 15 33 p = 0.274 3
GlyR α1βS321F 148 ± 27 7 p = 0.32 4.1 ± 0.7 7 p = 0.14 73 ± 4 0 23 p = 0.0565 3
GlyR α1βA455P 122 ± 4 4 p = 0.28 6.6 ± 1.1 8 *p = 0.027 92 ± 17 8 47 *p = 0.0228 3

Significance values: *p < 0.05; ***p < 0.001, n = number of experiments.

 Interaction of Glycine Receptor β Subunit Variants With Endogenous Gephyrin and Synaptic Localization in Transfected Primary Neurons

The novel GlyR β missense variants still interact with the scaffold protein gephyrin in vitro but alter the area or perimeter of intracellular GlyR β-gephyrin accumulations. To assess whether the GlyR-gephyrin interaction is also modified in a synaptic context, hippocampal neurons were transfected with the GlyR α1 and β WT or α1βx variants. Synapsin was used as a marker of synapses. Consistent with previous reports, endogenous gephyrin formed dendritic microclusters. Similarly, the myc-tagged GlyR β subunit and βx variants exhibited clusters along the dendrites of the hippocampal neurons (Figure 7A). However, large intracellular accumulations of GlyR β and gephyrin were not evident. Quantification of gephyrin versus GlyR β at synaptic sites, however, revealed a significant reduction of synaptic βY252S (p = 0.0124) and βA455P (p = 0.0208) (Figure 7B and Table 5). Therefore, in addition to the observed impairment of ion channel function, the GlyR β variants βY252S and βA455P revealed reduced synaptic localization that could contribute to the pathology in individuals with these missense mutations.

GlyR β variants form clusters with endogenous gephyrin but exhibit less synaptic localization. (A) Hippocampal neurons transfected with α1β WT and α1βx variants. The GlyR β subunit was detected with a myc-antibody (cyan), as well as endogenous gephyrin (yellow), and synapsin (magenta). White boxes indicate dendritic areas shown in the enlarged images on the right. White open arrowheads show co-localization of GlyR β in gephyrin-positive and synapsin-positive clusters. Scale bar refers to 25 μm. (B) Quantification of GlyR β-positive synapses. Calculation was performed from 40 to 92 dendrites (n = 40–92) from transfected neurons obtained from two independent experiments. A ratio of myc-GlyR β-positive synapses versus gephyrin-positive synapses was estimated and is given as β-positive synapses in %. Level of significance *p < 0.05.

Quantification of synaptic localization of GlyR βx variants.

GlyR variant β-positive synapses (%) p-values n
GlyR α1β 90 ± 3 74
GlyR α1βY252S 87 ± 3 *p = 0.0124 95
GlyR α1βS321F 78 ± 3 p = 0.9 40
GlyR α1βA455P 81 ± 2 *p = 0.0208 85

Significance values: *p < 0.05, n = number of dendrites used for calculation from two independent experiments.

 Discussion

In the present article, we identified functional alterations for the novel GlyR β variants Y252S, S321F, and A455P, that were identified in individuals with startle disease. The most common affected genes are GLRA1 encoding the GlyR α1 subunit and SLC6A5 encoding the glycine transporter 2, followed by GLRB encoding the β subunit (Rees et al., 2006; Harvey et al., 2008; Chung et al., 2013; James et al., 2013; Bode and Lynch, 2014). The β subunit is a key component of adult heteromeric α1β GlyRs at synaptic sites (Meier and Grantyn, 2004). Dominant mutations in GlyR α1 mainly affect the M1-M2 domains and the connecting extracellular loop and uncouple agonist binding from channel gating. By contrast, most recessive mutations result in protein truncation, or impair protein trafficking, reducing or eliminating GlyR expression at the cell surface as a consequence (Villmann et al., 2009). The molecular mechanisms underlying GlyR β subunit mutations are less well understood (Chung et al., 2013; James et al., 2013). Studies concentrated on heterologous expression of α1β heteromers in transfected cells. Chung et al., described reduced chloride ion influx rates accompanied by decreased surface expression for GlyR β variants independent of the mutant location in the ECD or transmembrane segments. In addition, James et al. (2013) reported the identification of a spontaneous active channel for the mutation βL285R localized in the M2 domain that caused spontaneous channel opening as well as βM177R (ECD) and βW310C (M3) which resulted in decreased maximal currents. In this study, we assessed three GLRB mutations (Y252S, S321F, and A455P) that are all localized in different transmembrane segments: M1, M3, and M4, respectively.

All three β variants Y252S, S321F, and A455P were able to leave the ER, pass the ERGIC (ER-Golgi intermediate compartment), the cis-Golgi, and insert into the cellular membrane. We did not detect GlyR β protein accumulations in any of these compartments that could reflect impaired receptor biogenesis or ER-associated degradation (Valkova et al., 2011). Although whole cell GlyR β protein analysis revealed slight decreases in the expression level, the observed differences lacked significance. Efforts to quantitatively estimate the surface expression level of the GlyR β variants failed but immunostainings clearly demonstrated that β subunits co-localized with the membrane marker GAP-43. Therefore, our data are in contrast to most recessive GlyR α1 variants and previously reported β subunit variants that significantly altered receptor trafficking (Chung et al., 2013; Schaefer et al., 2015).

The GlyR β subunit is transported together with the α1 subunit to the cellular surface (Kuhse et al., 1993). Without the α1 subunit, homomeric β subunit GlyRs cannot generate functional ion channels. Previously, it was thought that the β subunit only represented a structural component of the GlyR complex that was important for interactions with gephyrin, so enabling synaptic clustering. However, Grudzinska et al. (2005) identified critical residues in the β subunit located in β sheets β2 (R86) and β7 (E180) that contribute to ligand binding in heteromeric α1β receptors (Grudzinska et al., 2005). The β variants Y252S, S321F, and A455P are not localized in the ECD or close to the proposed residues involved in ligand binding. Missense mutations in a transmembrane segment might, however, impact the steric transduction coupling ligand binding to ion channel opening. Following agonist binding an anticlockwise rotation around the pore axis is initiated thus leading to an anticlockwise rotation of the entire transmembrane domains of all five subunits (Du et al., 2015). The transmembrane domains represent α-helical elements with stacking interactions between aromatic residues localized in the same or adjacent helices (Haeger et al., 2010; James et al., 2013; Tang and Lummis, 2018). The intramembrane aromatic residues are important for pentameric assembly and ion channel function, e.g., allosteric modulation and interaction with lipids (Carswell et al., 2015; Sridhar et al., 2021). The mutation of the aromatic Y252 in the M1 domain into the hydrophilic serine in the GlyR β subunit results in loss of an important interaction to another Y492 in M4 and was predicted to alter ion channel properties. A second GlyR β subunit mutation S321F, results in an aromatic residue substituting for a polar serine. This was predicted to stabilize the M3 structure via an additional interaction with neighboring aromatic ring structures. The third β subunit mutation A455P introduces a kink in the M4 domain, although the overall structure is only marginally affected, flexibility might be altered.

In the GlyR α1 subunit, a tyrosine, is also found at the corresponding amino acid position to GlyR β Y252. A mutation of this tyrosine (Y228C) has been reported in an individual with startle disease, but this has not yet been investigated at the functional level (Forsyth et al., 2007). Other hyperekplexia mutations affecting residues around Y228 in GlyR α1 mainly affected glycine potency (Humeny et al., 2002; Chung et al., 2010; Bode et al., 2013). For the β subunit mutant Y252S, we found increased EC50 values suggestive of a reduced glycine potency, while expression levels and maximal currents in response to glycine were unaffected. Mutations of aromatic residues in the M4 domain (W407R in α1 and Y470C in β) found in individuals with startle disease significantly decrease GlyR levels or are retained in the ER (Chung et al., 2013; Schaefer et al., 2015). Hence, data from the GlyR β mutant Y252S illustrate that impaired protein expression is not a general mechanism following disruption of stacking interactions of aromatic residues within or between transmembrane helices.

The GlyR β variant S321F did not exhibit any obvious expression or trafficking deficits and no functional alterations were observed on heterologous expression in HEK-293 cells. This is in line with the structural prediction that this mutant might have a rather stabilizing effect. However, this does not explain why the patient shows characteristic symptoms of hyperekplexia. As this patient also carries a second mutation affecting the splice donor site of intron 4 of the GLRB gene, one might assume that the second mutation may significantly contribute to the phenotype in this patient (Lee et al., 2013). Disruption of a splice site can cause aberrant splicing und thus severely affect protein expression level. A reduction to less than 10% of the full-length GlyR β subunit result in typical symptoms of startle disease as observed in the spontaneous mouse model spastic (Mulhardt et al., 1994).

The mutant A455P represents a gain-of-function, leaving the EC50 unaffected. The increase in glycine efficacy is not accompanied by an increase in surface expressed receptors. Gain of function mutations have also been identified for the GlyR α1 subunit (I43F, Y128C, W170S, Q226E, V280M, and R414H). Increased glycine sensitivity and spontaneous channel activation have been mainly associated with gain-of-function mutations in the GlyR α1 subunit. Clinically, the hyperekplexia phenotype induced by a gain-of-function mutation is not different from a loss-of-function mutation with clonazepam being an effective treatment in many cases (Bode and Lynch, 2014).

In vivo, the GlyR complex is anchored at synaptic sites via the β-gephyrin interaction (Kim et al., 2006). The interaction site at the receptor is localized in the large intracellular loop between M3 and M4 (Meyer et al., 1995). Although none of the amino acid substitutions in the β subunit we studied directly affects the interaction site, structural changes in the transmembrane segments might also impact the overall structure and presentation of the gephyrin binding motif. The structure of the M3-M4 intracellular loop is not yet described except for short amino acid sequences following M3 and at the N-terminal end of M4 (Unwin, 2005). The GlyR β mutants localized in transmembrane domains M1, M3, and M4 were investigated in the presence of gephyrin. The observed changes at the functional level were decreased glycine potency for Y252S and an increased glycine efficacy for A455P. These parameters were more pronounced in the presence of gephyrin, while S321F did not display any functional alterations either with or without gephyrin. Interestingly, an increased number of α1 homomers was noticed when the β mutants were co-expressed with the α1 subunit and gephyrin compared to co-expression in the absence of gephyrin arguing for inefficient incorporation of the β subunit mutants into functional receptors in the presence of gephyrin. Gephyrin has been reported earlier to trap α1β receptors in large intracellular aggregates in heterologous expression systems at least (Kins et al., 2000; Grosskreutz et al., 2001).

In the presence of the GlyR α1 and β subunits, gephyrin aggregates increased in number and concomitantly in area and perimeter. We found large cytoplasmic aggregates for the β variants and gephyrin in the cellular cytoplasm with significant increases in area and perimeter for S321F and A455P. These data suggest that inefficient incorporation into functional GlyRs might underlie the pathomechanisms for S321F and A455P. At synapses, inefficient incorporation into the GlyRs would hinder synaptic localization and probably as a consequence inhibitory neurotransmission. Indeed, less GlyR β was found for the functionally impaired variants Y252S and A455P at synaptic sites in transfected hippocampal neurons. Our data strongly suggest that structural changes in the GlyR β subunit have an impact on GlyR β-gephyrin interactions, synaptic localization and thus the intermolecular crosstalk between α and β subunits and gephyrin (Patrizio et al., 2017). As a consequence, GlyR α1 homomers are the favored receptor configuration which are located at extrasynaptic but not synaptic sites. Moreover, aromatic substitutions have a substantial effect on M4/M1-M3 interactions and interactions with surrounding lipids, also altering ion channel function (Haeger et al., 2010; Carswell et al., 2015; Henault et al., 2019; Sridhar et al., 2021).

In summary, the novel GlyR β subunit mutations result in loss- or gain-of-function and/or impaired synaptic GlyR clustering due to altered interactions between GlyR β and gephyrin. Together, our data provide novel insights into the contribution of the GlyR β subunit to startle disease pathology.

 Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

 Ethics Statement

The animal study was reviewed and approved by the local veterinary authority (Veterinäramt der Stadt Würzburg) and Committee on the Ethics of Animal Experiments, i.e., Regierung von Unterfranken, Würzburg (License number FBVVL 568/200-324/13).

 Author Contributions

CV, NS, RH, and CS participated in research design. IP, A-LE, NS, RH, CV, and VK conducted the experiments. IP, A-LE, NS, and VK performed the data analysis. CV, RH, and NS wrote the manuscript. All authors contributed to the article and approved the submitted version.

 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Funding

This work was funded by the Deutsche Forschungsgemeinschaft (DFG) VI586 to CV and SO 328/13-1 to CS, Medical Research Council (G0601585 to RH), and Action Medical Research (1966 to RH). VK is a EMBO long-term postdoctoral fellow at MRC LMB (ALTF 137-2019).

We would like to thank Nadine Vornberger and Dana Wegmann for excellent technical assistance.

 References Aboheimed G. Alrasheed M. Salih M. Alowain A. Alsagob M. Almass R. (2019). Novel glycine receptor variants identified in startle disease patients. Eur. J. Hum. Genet. 27 1466–1467. Arnold K. Bordoli L. Kopp J. Schwede T. (2006). The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22 195–201. 10.1093/bioinformatics/bti770 16301204 Atak S. Langlhofer G. Schaefer N. Kessler D. Meiselbach H. Delto C. (2015). Disturbances of ligand potency and enhanced degradation of the human glycine receptor at affected positions G160 and T162 originally identified in patients suffering from hyperekplexia. Front. Mol. Neurosci. 8:79. 10.3389/fnmol.2015.00079 26733802 Bode A. Lynch J. W. (2014). The impact of human hyperekplexia mutations on glycine receptor structure and function. Mol. Brain 7:2. 10.1186/1756-6606-7-2 24405574 Bode A. Wood S. E. Mullins J. G. Keramidas A. Cushion T. D. Thomas R. H. (2013). New hyperekplexia mutations provide insight into glycine receptor assembly, trafficking, and activation mechanisms. J. Biol. Chem. 288 33745–33759. 10.1074/jbc.m113.509240 24108130 Bormann J. Rundstrom N. Betz H. Langosch D. (1993). Residues within transmembrane segment M2 determine chloride conductance of glycine receptor homo- and hetero-oligomers. Embo J. 12 3729–3737. 10.1002/j.1460-2075.1993.tb06050.x Carswell C. L. Henault C. M. Murlidaran S. Therien J. P. D. Juranka P. F. Surujballi J. A. (2015). Role of the fourth transmembrane alpha helix in the allosteric modulation of pentameric ligand-gated ion channels. Structure 23 1655–1664. 10.1016/j.str.2015.06.020 26235032 Carvajal-Gonzalez A. Leite M. I. Waters P. Woodhall M. Coutinho E. Balint B. (2014). Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 137(Pt 8), 2178–2192. 10.1093/brain/awu142 24951641 Chung S. K. Bode A. Cushion T. D. Thomas R. H. Hunt C. Wood S. E. (2013). GLRB is the third major gene of effect in hyperekplexia. Hum. Mol. Genet. 22 927–940. 10.1093/hmg/dds498 23184146 Chung S. K. Vanbellinghen J. F. Mullins J. G. Robinson A. Hantke J. Hammond C. L. (2010). Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia. J. Neurosci. 30 9612–9620. 10.1523/jneurosci.1763-10.2010 20631190 Di Tommaso P. Moretti S. Xenarios I. Orobitg M. Montanyola A. Chang J. M. (2011). T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension. Nucleic Acids Res. 39 W13–W17. Du J. Lu W. Wu S. Cheng Y. Gouaux E. (2015). Glycine receptor mechanism elucidated by electron cryo-microscopy. Nature 526 224–229. 10.1038/nature14853 26344198 Durisic N. Godin A. G. Wever C. M. Heyes C. D. Lakadamyali M. Dent J. A. (2012). Stoichiometry of the human glycine receptor revealed by direct subunit counting. J. Neurosci. 32 12915–12920. 10.1523/jneurosci.2050-12.2012 22973015 Emsley P. Cowtan K. (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60(Pt 12 Pt 1), 2126–2132. 10.1107/s0907444904019158 15572765 Forsyth R. J. Gika A. D. Ginjaar I. Tijssen M. A. (2007). A novel GLRA1 mutation in a recessive hyperekplexia pedigree. Mov. Disord. 22 1643–1645. 10.1002/mds.21574 17534957 Goddard T. D. Huang C. C. Meng E. C. Pettersen E. F. Couch G. S. Morris J. H. (2018). UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27 14–25. 10.1002/pro.3235 28710774 Grosskreutz Y. Hermann A. Kins S. Fuhrmann J. C. Betz H. Kneussel M. (2001). Identification of a gephyrin-binding motif in the GDP/GTP exchange factor collybistin. Biol. Chem. 382 1455–1462. 10.1515/bc.2001.179 11727829 Grudzinska J. Schemm R. Haeger S. Nicke A. Schmalzing G. Betz H. (2005). The beta subunit determines the ligand binding properties of synaptic glycine receptors. Neuron 45 727–739. 10.1016/j.neuron.2005.01.028 15748848 Haeger S. Kuzmin D. Detro-Dassen S. Lang N. Kilb M. Tsetlin V. (2010). An intramembrane aromatic network determines pentameric assembly of Cys-loop receptors. Nat. Struct. Mol. Biol. 17 90–98. 10.1038/nsmb.1721 20023641 Harvey K. Duguid I. C. Alldred M. J. Beatty S. E. Ward H. Keep N. H. (2004). The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering. J. Neurosci. 24 5816–5826. 10.1523/jneurosci.1184-04.2004 15215304 Harvey R. J. Topf M. Harvey K. Rees M. I. (2008). The genetics of hyperekplexia: more than startle! Trends Genet. 24 439–447. 10.1016/j.tig.2008.06.005 18707791 Henault C. M. Govaerts C. Spurny R. Brams M. Estrada-Mondragon A. Lynch J. (2019). A lipid site shapes the agonist response of a pentameric ligand-gated ion channel. Nat. Chem. Biol. 15 1156–1164. Huang X. Chen H. Michelsen K. Schneider S. Shaffer P. L. (2015). Crystal structure of human glycine receptor-alpha3 bound to antagonist strychnine. Nature 526 277–280. 10.1038/nature14972 26416729 Humeny A. Bonk T. Becker K. Jafari-Boroujerdi M. Stephani U. Reuter K. (2002). A novel recessive hyperekplexia allele GLRA1 (S231R): genotyping by MALDI-TOF mass spectrometry and functional characterisation as a determinant of cellular glycine receptor trafficking. Eur. J. Hum. Genet. 10 188–196. 10.1038/sj.ejhg.5200779 11973623 James V. M. Bode A. Chung S. K. Gill J. L. Nielsen M. Cowan F. M. (2013). Novel missense mutations in the glycine receptor beta subunit gene (GLRB) in startle disease. Neurobiol. Dis. 52 137–149. 10.1016/j.nbd.2012.12.001 23238346 Kim E. Y. Schrader N. Smolinsky B. Bedet C. Vannier C. Schwarz G. (2006). Deciphering the structural framework of glycine receptor anchoring by gephyrin. Embo J. 25 1385–1395. 10.1038/sj.emboj.7601029 16511563 Kins S. Betz H. Kirsch J. (2000). Collybistin, a newly identified brain-specific GEF, induces submembrane clustering of gephyrin. Nat. Neurosci. 3 22–29. 10.1038/71096 10607391 Kuhse J. Laube B. Magalei D. Betz H. (1993). Assembly of the inhibitory glycine receptor: identification of amino acid sequence motifs governing subunit stoichiometry. Neuron 11 1049–1056. 10.1016/0896-6273(93)90218-g Langlhofer G. Villmann C. (2016). The intracellular loop of the glycine receptor: it’s not all about the size. Front. Mol. Neurosci. 9:41. 10.3389/fnmol.2016.00041 27330534 Lee C. G. Kwon M. J. Yu H. J. Nam S. H. Lee J. Ki C. S. (2013). Clinical features and genetic analysis of children with hyperekplexia in Korea. J. Child Neurol. 28 90–94. 10.1177/0883073812441058 22532536 Liu Q. Wong-Riley M. T. (2013). Postnatal development of glycine receptor subunits alpha1, alpha2, alpha3, and beta immunoreactivity in multiple brain stem respiratory-related nuclear groups of the rat. Brain Res. 1538 1–16. 10.1016/j.brainres.2013.09.028 24080401 Lynch J. W. (2004). Molecular structure and function of the glycine receptor chloride channel. Physiol. Rev. 84 1051–1095. 10.1152/physrev.00042.2003 15383648 Maric H. M. Hausrat T. J. Neubert F. Dalby N. O. Doose S. Sauer M. (2017). Gephyrin-binding peptides visualize postsynaptic sites and modulate neurotransmission. Nat. Chem. Biol. 13 153–160. 10.1038/nchembio.2246 27893705 Meier J. Grantyn R. (2004). A gephyrin-related mechanism restraining glycine receptor anchoring at GABAergic synapses. J. Neurosci. 24 1398–1405. 10.1523/jneurosci.4260-03.2004 14960612 Meier J. Meunier-Durmort C. Forest C. Triller A. Vannier C. (2000). Formation of glycine receptor clusters and their accumulation at synapses. J. Cell Sci. 113(Pt 15), 2783–2795. 10.1242/jcs.113.15.2783 Meyer G. Kirsch J. Betz H. Langosch D. (1995). Identification of a gephyrin binding motif on the glycine receptor beta subunit. Neuron 15 563–572. 10.1016/0896-6273(95)90145-0 Morelli G. Avila A. Ravanidis S. Aourz N. Neve R. L. Smolders I. (2017). Cerebral cortical circuitry formation requires functional glycine receptors. Cereb. Cortex 27 1863–1877. Mulhardt C. Fischer M. Gass P. Simon-Chazottes D. Guenet J. L. Kuhse J. (1994). The spastic mouse: aberrant splicing of glycine receptor beta subunit mRNA caused by intronic insertion of L1 element. Neuron 13 1003–1015. Notredame C. Higgins D. G. Heringa J. (2000). T-Coffee: a novel method for fast and accurate multiple sequence alignment. J. Mol. Biol. 302 205–217. 10.1006/jmbi.2000.4042 10964570 Patrizio A. Renner M. Pizzarelli R. Triller A. Specht C. G. (2017). Alpha subunit-dependent glycine receptor clustering and regulation of synaptic receptor numbers. Sci. Rep. 7:10899. Pribilla I. Takagi T. Langosch D. Bormann J. Betz H. (1992). The atypical M2 segment of the beta subunit confers picrotoxinin resistance to inhibitory glycine receptor channels. Embo J. 11 4305–4311. 10.1002/j.1460-2075.1992.tb05529.x Rauschenberger V. Von Wardenburg N. Schaefer N. Ogino K. Hirata H. Lillesaar C. (2020). Glycine receptor autoantibodies impair receptor function and induce motor dysfunction. Ann. Neurol. 88 544–561. 10.1002/ana.25832 32588476 Rees M. I. Harvey K. Pearce B. R. Chung S. K. Duguid I. C. Thomas P. (2006). Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease. Nat. Genet. 38 801–806. 10.1038/ng1814 16751771 Schaefer N. Kluck C. J. Price K. L. Meiselbach H. Vornberger N. Schwarzinger S. (2015). Disturbed neuronal ER-Golgi sorting of unassembled glycine receptors suggests altered subcellular processing is a cause of human hyperekplexia. J. Neurosci. 35 422–437. 10.1523/jneurosci.1509-14.2015 25568133 Schaefer N. Roemer V. Janzen D. Villmann C. (2018). Impaired glycine receptor trafficking in neurological diseases. Front. Mol. Neurosci. 11:291. 10.3389/fnmol.2018.00291 30186111 Schindelin J. Arganda-Carreras I. Frise E. Kaynig V. Longair M. Pietzsch T. (2012). Fiji: an open-source platform for biological-image analysis. Nat. Methods 9 676–682. 10.1038/nmeth.2019 22743772 Sridhar A. Lummis S. C. R. Pasini D. Mehregan A. Brams M. Kambara K. (2021). Regulation of a pentameric ligand-gated ion channel by a semi-conserved cationic-lipid binding site. J. Biol. Chem. 297:100899. 10.1016/j.jbc.2021.100899 34157288 Tang B. Lummis S. C. R. (2018). The roles of aromatic residues in the glycine receptor transmembrane domain. BMC Neurosci. 19:53. 10.1186/s12868-018-0454-8 30189850 Turecek R. Trussell L. O. (2001). Presynaptic glycine receptors enhance transmitter release at a mammalian central synapse. Nature 411 587–590. 10.1038/35079084 11385573 Unwin N. (2005). Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J. Mol. Biol. 346 967–989. 10.1016/j.jmb.2004.12.031 15701510 Valkova C. Albrizio M. Roder I. V. Schwake M. Betto R. Rudolf R. (2011). Sorting receptor Rer1 controls surface expression of muscle acetylcholine receptors by ER retention of unassembled alpha-subunits. Proc. Natl. Acad. Sci. U.S.A. 108 621–625. 10.1073/pnas.1001624108 21187406 Villmann C. Oertel J. Melzer N. Becker C. M. (2009). Recessive hyperekplexia mutations of the glycine receptor alpha1 subunit affect cell surface integration and stability. J. Neurochem. 111 837–847. 10.1111/j.1471-4159.2009.06372.x 19732286 Xiong W. Chen S. R. He L. Cheng K. Zhao Y. L. Chen H. (2014). Presynaptic glycine receptors as a potential therapeutic target for hyperekplexia disease. Nat. Neurosci. 17 232–239. 10.1038/nn.3615 24390226 Yu J. Zhu H. Lape R. Greiner T. Du J. Lu W. (2021). Mechanism of gating and partial agonist action in the glycine receptor. Cell 184 957–968.e21.